- Home
- YSG vs IMMP Comparison
YSG vs IMMP Comparison
Compare YSG & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YSG
- IMMP
- Stock Information
- Founded
- YSG 2016
- IMMP 1987
- Country
- YSG China
- IMMP Australia
- Employees
- YSG N/A
- IMMP N/A
- Industry
- YSG Package Goods/Cosmetics
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- YSG Consumer Discretionary
- IMMP Health Care
- Exchange
- YSG Nasdaq
- IMMP Nasdaq
- Market Cap
- YSG 306.5M
- IMMP 304.0M
- IPO Year
- YSG 2020
- IMMP N/A
- Fundamental
- Price
- YSG $3.17
- IMMP $1.98
- Analyst Decision
- YSG
- IMMP Buy
- Analyst Count
- YSG 0
- IMMP 2
- Target Price
- YSG N/A
- IMMP $8.50
- AVG Volume (30 Days)
- YSG 81.4K
- IMMP 71.7K
- Earning Date
- YSG 03-05-2025
- IMMP 02-27-2025
- Dividend Yield
- YSG N/A
- IMMP N/A
- EPS Growth
- YSG N/A
- IMMP N/A
- EPS
- YSG N/A
- IMMP N/A
- Revenue
- YSG $472,960,724.00
- IMMP $2,563,302.00
- Revenue This Year
- YSG $2.29
- IMMP N/A
- Revenue Next Year
- YSG $5.70
- IMMP $47.79
- P/E Ratio
- YSG N/A
- IMMP N/A
- Revenue Growth
- YSG N/A
- IMMP 9.59
- 52 Week Low
- YSG $1.99
- IMMP $1.66
- 52 Week High
- YSG $5.22
- IMMP $3.34
- Technical
- Relative Strength Index (RSI)
- YSG 37.70
- IMMP 47.28
- Support Level
- YSG $3.13
- IMMP $1.89
- Resistance Level
- YSG $3.31
- IMMP $2.04
- Average True Range (ATR)
- YSG 0.15
- IMMP 0.08
- MACD
- YSG 0.04
- IMMP 0.00
- Stochastic Oscillator
- YSG 24.53
- IMMP 31.48
About YSG Yatsen Holding Limited
Yatsen Holding Ltd is engaged in the retail business of beauty products, skincare items, and other cosmetic products. The Group's principal operations are currently organized into three segments on a product category basis, namely Color Cosmetics Brands, Skincare Brands, and others. The company's majority of revenue is generated from sales of Color Cosmetics Brands.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.